H.C. Wainwright reaffirmed a Buy rating on Cartesian Therapeutics shares, maintaining the $45.00 price target, representing a ...

Julian Harrison, an analyst from BTIG, reiterated the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated price ...

Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at ...

This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...

Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol ...

(RTTNews) - Cartesian Therapeutics, Inc. (RNAC), a clinical-stage biotechnology company, on Monday announced that it has received written agreement from the U.S. Food and Drug Administration or ...

Trial on track to commence in 1H25FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage ...

Cartesian Therapeutics reported earnings per share of 54 cents. This was above the analyst estimate for EPS of -$1.19. The company reported revenue of $33.45 million.

FREDERICK, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering ...

Cartesian Therapeutics (RNAC) announced the granting of inducement awards to four new employees. On December 12, 2024, the Company issued to these employees options to purchase an aggregate of ...

Cartesian Therapeutics develops mRNA cell therapies for autoimmune diseases, leveraging three modalities: mRNA CAR-T, mRNA MSC, and mRNA in situ. Lead asset Descartes-08 targets myasthenia gravis ...

Cartesian Therapeutics, Inc. operates as a clinical-stage biotechnology company. It provides mRNA cell therapies for the treatment of autoimmune diseases. It operates in research and development ...